Get the Daily Brief
Latest Biotech News
Neumora advances NLRP3 obesity program after competitor setbacks
Neumora Therapeutics is pressing forward with an NLRP3 inhibitor program for obesity after competitors failed to deliver weight‑loss efficacy. Preclinical data released by the company show that...
Implantable CMOS imager records single‑neuron activity deep in brain
Researchers unveiled an implantable complementary metal–oxide–semiconductor (CMOS) fluorescence imager that achieves single‑neuron resolution deep within brain tissue. The device integrates...
MARTi brings real‑time nanopore metagenomics to field surveillance
Researchers at the Earlham Institute released MARTi, an open‑source software suite that performs real‑time analysis and visualization of nanopore metagenomic data for pathogen detection,...
Novartis bets $12B on RNA delivery: Avidity deal expands neuromuscular pipeline
Novartis announced it will acquire Avidity Biosciences for roughly $12 billion, purchasing a late-stage pipeline built on antibody-oligonucleotide conjugates (AOCs) designed to deliver RNA to...
CRISPR safety alarm: Intellia halts two late‑stage trials after liver toxicity
Intellia Therapeutics paused enrollment and dosing in two phase 3 trials of its in vivo CRISPR candidate after a participant was hospitalized with severe liver injury. The company halted screening...
Zenas posts striking mid‑stage MS signal: Obexelimab slashes new lesions
Zenas Biopharma reported mid‑stage data showing its bifunctional antibody obexelimab cut new gadolinium‑enhancing brain lesions by 95% over 12 weeks in relapsing multiple sclerosis in the...
BridgeBio advances toward approval after Phase III win — FDA meeting planned
BridgeBio reported positive Phase 3 interim results for its limb‑girdle muscular dystrophy candidate, showing statistically significant improvements on a muscle‑stability biomarker and functional...
Leqembi cleared in Canada: Eisai and Biogen land conditional approval
Health Canada issued a Notice of Compliance with Conditions for Eisai/Biogen’s lecanemab (LEQEMBI) for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are...
Bayer wins FDA OK for non‑hormonal menopause pill — Market competition heats up
The FDA approved Bayer’s Lynkuet, a once‑daily non‑hormonal treatment targeting NK1 and NK3 receptors to reduce moderate‑to‑severe vasomotor symptoms of menopause. Approval was supported by three...
Hemab raises $157M to tackle rare coagulation disorders — Late‑stage trials ahead
Hemab Therapeutics closed a $157 million financing to advance a portfolio aimed at underserved bleeding disorders, including two programs already in clinical testing. The round, led by Sofinnova...
Guardant joins Zephyr AI to speed genomic biomarker discovery
Guardant Health struck a partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its oncology test platform with Zephyr’s analytics to accelerate discovery of genomic...
GLP‑1 supply and science: USP standards released as real‑world nonresponse questions rise
The U.S. Pharmacopeia released analytical reference materials and guidance to help manufacturers ensure purity and detect product‑ and process‑related impurities for GLP‑1 peptides amid surging...
Revvity leans on newborn screening to drive diagnostics growth
Revvity reported third‑quarter diagnostics revenue growth driven by its newborn screening business and immunodiagnostics, citing CE marking for an updated lysosomal storage disease panel and a...
Novartis to buy Avidity for $12B — bet on RNA neuromuscular drugs
Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, taking ownership of three late-stage antibody-oligonucleotide conjugate (AOC) programs aimed at Duchenne muscular dystrophy,...
Intellia pauses CRISPR trials after liver toxicity hospitalisation
Intellia Therapeutics halted enrollment and dosing across two late‑stage CRISPR trials following a volunteer’s hospitalization with severe liver injury linked to its transthyretin amyloidosis...
Zenas’ obexelimab slashes new MS lesions — a convincing mid‑stage readout
Zenas Biopharma reported that obexelimab reduced the cumulative number of new gadolinium‑enhancing brain lesions by about 95% over 12 weeks in a Phase 2 trial in relapsing multiple sclerosis. The...
Health Canada clears lecanemab for early Alzheimer’s — conditional authorization
Health Canada issued a Notice of Compliance with Conditions for LEQEMBI (lecanemab), authorizing Eisai and Biogen’s monoclonal antibody for adults with mild cognitive impairment or mild dementia...
FDA approves Bayer’s non‑hormonal menopause pill Lynkuet — new competition
The FDA approved Lynkuet, Bayer’s once‑daily non‑hormonal oral therapy for moderate‑to‑severe vasomotor symptoms of menopause. Approval relied on three late‑stage trials that demonstrated...
Hemab raises $157M to push coagulation disorder pipeline forward
Hemab Therapeutics closed a $157 million financing to advance a portfolio of clotting‑disorder programs, including two candidates already in clinical testing. The Series C was led by Sofinnova...
BridgeBio pivots filing plans after Phase 3 rare‑disease success
BridgeBio reported positive interim Phase 3 data in a rare muscular dystrophy study and said it will adjust its regulatory strategy and meet with the FDA to discuss a path to approval. The company...